Donald Hooker – Keybanc

Keybanc

A Keybanc analyst with 8 tracked ratings spanning 8 distinct tickers has a 12.5% success rate on the captured sample, primarily covering two sources.

Aggregated from multiple market-data sources

Total ratings

Tickers covered

Sources

Aggregated

Latest rating

4 years ago

2022-02-23 00:00:00+00

Track record

Aggregated

13% success rate

Bullish: 7
Hold: 0
Bearish: 0

Aggregated

Not available

Bullish: 1
Hold: 0
Bearish: 0

Recent ratings

Ticker	Date	Rating	Price target	Source
TDOC	2022-02-23	buy	$100.00	Aggregated
TDOCTELADOC HEALTH INC	2022-02-23	unknown	$100.00	Aggregated
CRL	2022-02-17	buy	$390.00	Aggregated
CRLCHARLES RIVER LABORATORIES INTERNATIONAL INC.	2022-02-17	unknown	$390.00	Aggregated
IQV	2021-11-17	buy	$290.00	Aggregated
IQVIQVIA HOLDINGS INC	2021-11-17	unknown	$290.00	Aggregated
SYNH	2021-11-04	buy	$105.00	Aggregated
SYNH-	2021-11-04	unknown	$105.00	Aggregated
DGX	2021-09-01	buy	$168.00	Aggregated
DGXQUEST DIAGNOSTICS, INC.	2021-09-01	unknown	$168.00	Aggregated
PHR	2021-07-12	buy	$73.00	Aggregated
PHRPHREESIA INC	2021-07-12	unknown	$73.00	Aggregated
RXRX	2021-05-11	buy	$36.00	Aggregated
RXRXRECURSION PHARMACEUTICALS INC - ORDINARY SHARES - CLASS A	2021-05-11	unknown	$36.00	Aggregated
INCR	2017-11-13	buy	$46.00	Aggregated

Tickers covered(15)

Ticker	Ratings	Last rating	Sources
TDOC	2	2022-02-23	Aggregated
TDOCTELADOC HEALTH INC	1	2022-02-23	Aggregated
CRL	2	2022-02-17	Aggregated
CRLCHARLES RIVER LABORATORIES INTERNATIONAL INC.	1	2022-02-17	Aggregated
IQV	2	2021-11-17	Aggregated
IQVIQVIA HOLDINGS INC	1	2021-11-17	Aggregated
SYNH	2	2021-11-04	Aggregated
SYNH-	1	2021-11-04	Aggregated
DGX	2	2021-09-01	Aggregated
DGXQUEST DIAGNOSTICS, INC.	1	2021-09-01	Aggregated
PHR	2	2021-07-12	Aggregated
PHRPHREESIA INC	1	2021-07-12	Aggregated
RXRX	2	2021-05-11	Aggregated
RXRXRECURSION PHARMACEUTICALS INC - ORDINARY SHARES - CLASS A	1	2021-05-11	Aggregated
INCR	1	2017-11-13	Aggregated

Methodology differs by source. Track records are aggregated from multiple sources; scoring methodology and scales differ by source and values are not directly comparable. Coverage is sourced from publicly-aggregated analyst activity. Past performance does not guarantee future results. Not investment advice.